Towards the development of antistaphylococcal immunotherapy

Koedijk, D., 2017, [Groningen]: University of Groningen. 183 p.

Research output: ThesisThesis fully internal (DIV)

Copy link to clipboard


  • Title and contents

    Final publisher's version, 345 KB, PDF document

  • Chapter 1

    Final publisher's version, 798 KB, PDF document

  • Chapter 2

    Final publisher's version, 1.09 MB, PDF document

  • Chapter 3

    Final publisher's version, 941 KB, PDF document

  • Chapter 4

    Final publisher's version, 1.02 MB, PDF document

  • Chapter 5

    Final publisher's version, 1.59 MB, PDF document

  • Chapter 6

    Final publisher's version, 1.37 MB, PDF document

  • Chapter 7

    Final publisher's version, 489 KB, PDF document

  • Chapter 8

    Final publisher's version, 435 KB, PDF document

  • Appendices

    Final publisher's version, 353 KB, PDF document

  • Complete thesis

    Final publisher's version, 4.41 MB, PDF document

  • Propositions

    Final publisher's version, 258 KB, PDF document

  • Danny Koedijk
The World Health Organization predicts that infections caused by antibiotic resistant microbes will be the number one cause of deaths in 2050. Accordingly, methicillin-resistant Staphylococcus aureus (widely known as MRSA), was recently ranked 5th on the “WHO priority pathogens list” as a target for new antimicrobial therapies. Indeed, infections by MRSA are difficult to treat, and therefore new approaches for prevention and treatment of infections caused by this pathogen are urgently needed. Possible alternatives to antibiotics are active and passive immunization approaches, where patients are either vaccinated with the inactivated pathogen or some of the pathogen’s components, or with antibodies from an appropriate donor source. The present PhD research describes a pipeline that can be applied to develop such active or passive immunization approaches to protect frail individuals against infections by MRSA. Particular attention was attributed to proteins exposed on the surface of MRSA, especially a protein named IsaA. The developed pipeline was used to produce the IsaA protein for active immunization against MRSA, and a monoclonal antibody against IsaA for passive immunization. The results show that active vaccination with pure IsaA is challenging, possibly because the immune system may recognize the wrong end of this protein. However, at least in an animal model, the anti-IsaA antibody gives partial protection against S. aureus infection. Altogether, these results show that the pipeline that was developed to purify MRSA proteins and to raise antibodies against them represents a promising step towards the development of anti-MRSA immunotherapy.
Translated title of the contributionOp weg naar de ontwikkeling van een immuuntherapie tegen stafylokokken
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date21-Jun-2017
Place of Publication[Groningen]
Print ISBNs978-90-367-9875-4
Electronic ISBNs978-90-367-9874-7
Publication statusPublished - 2017

Download statistics

No data available

ID: 42604218